Raltegravir, elvitegravir, and metoogravir: The birth of "me-too" HIV-1 integrase inhibitors

  • Serrao E
  • Odde S
  • Ramkumar K
 et al. 
  • 53

    Readers

    Mendeley users who have this article in their library.
  • 110

    Citations

    Citations of this article.

Abstract

Merck's MK-0518, known as raltegravir, has recently become the first FDA-approved HIV-1 integrase (IN) inhibitor and has since risen to blockbuster drug status. Much research has in turn been conducted over the last few years aimed at recreating but optimizing the compound's interactions with the protein. Resulting me-too drugs have shown favorable pharmacokinetic properties and appear drug-like but, as expected, most have a highly similar interaction with IN to that of raltegravir. We propose that, based upon conclusions drawn from our docking studies illustrated herein, most of these me-too MK-0518 analogues may experience a low success rate against raltegravir-resistant HIV strains. As HIV has a very high mutational competence, the development of drugs with new mechanisms of inhibitory action and/or new active substituents may be a more successful route to take in the development of second- and third-generation IN inhibitors.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Erik Serrao

  • Srinivas Odde

  • Kavya Ramkumar

  • Nouri Neamati

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free